Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321005 | 0.85 | HSD11B1 (0.64) | HSD11B1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL3323691 | 0.85 | HSD11B1 (0.64) | HSD11B1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL3323414 | 0.83 | HSD11B1 (0.62) | HSD11B1CYP3A4KMT2ARAB9ALMNA | |
| SCHEMBL3323599 | 0.82 | HSD11B1 (0.60) | HSD11B1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL3321100 | 0.82 | HSD11B1 (0.65) | HSD11B1CYP3A4KMT2AALDH1A1HTT | |
| SCHEMBL3323853 | 0.81 | HSD11B1 (0.59) | HSD11B1CYP3A4KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3323029 | 0.80 | HSD11B1 (0.58) | HSD11B1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL3323602 | 0.80 | HSD11B1 (0.58) | HSD11B1CYP3A4KMT2ALMNAMEN1 | |
| SCHEMBL5297805 | 0.79 | HSD11B1 (0.57) | HSD11B1CYP3A4KMT2AALDH1A1RAB9A | |
| SCHEMBL3322979 | 0.77 | HSD11B1 (1.00) | HSD11B1CYP3A4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885CYP3A4 72/4885KMT2A 3083/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | HSD11B1 73/4885CYP3A4 100/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.